Celltrion said it aims to solidify its position as a leading biosimilar company for autoimmune diseases by presenting various studies related during the 2025 European Crohn’s and Colitis Organization (ECCO) Congress, being held from Wednesday to Saturday this week in Berlin, Germany.

As one of the premier global conferences on inflammatory bowel disease (IBD), ECCO provides a platform for the latest research, clinical advancements, and therapeutic developments. This year’s event has drawn over 8,000 IBD specialists worldwide, with Celltrion standing out as the only Korean company to host an independent promotional booth.

A key highlight of Celltrion’s presence at ECCO 2025 was the oral presentation by Professor Jean-Frédéric Colombel from the Icahn School of Medicine at Mount Sinai, New York.

He shared a post-hoc analysis of phase 3 clinical trial data on Remsima SC (ingredient: infliximab), marketed as Zymfentra in the U.S., focusing on its maintenance therapy in patients with moderate to severe ulcerative colitis (UC).

The findings demonstrated significant endoscopic and histological improvement in patients receiving Remsima SC maintenance therapy compared to the placebo group at week 54. Also, the data indicated a progressive increase in endoscopic normalization rates over time, reinforcing the benefits of sustained treatment with Remsima SC.

Celltrion is also unveiling three poster presentations on Friday (local time), offering further insights into Remsima SC’s efficacy. These studies explore dose escalation after loss of response, therapeutic outcomes based on disease location within the intestine, and the immunogenicity profile in moderate to severe Crohn’s disease (CD) patients.

In addition to research presentations, Celltrion is hosting a symposium titled “Early Intervention in IBD: Unlocking the Potential of Timely Advanced Treatment,” which will delve into the importance of early treatment strategies, emphasizing the potential advantages of initiating therapy with Remsima SC at an early stage.

At its dedicated exhibition booth, Celltrion is organizing expert-led seminars covering the long-term benefits of Remsima SC in IBD treatment and real-world prescription data on cases such as fistulizing Crohn’s disease and obese patients.

The recent launch of Steqeyma (ingredient: ustekinumab) in late 2024, which has expanded Celltrion’s IBD treatment option to four, also garnered interest from European IBD specialists during the conference.

Notably, Celltrion Vice Chairman for Global Sales Business Kim Hyoung-ki is personally leading strategic marketing activities at the event, conducting high-level meetings with global IBD experts.

The company has also set up a dedicated meeting space within its booth to facilitate in-depth discussions with local healthcare professionals, aiming to bolster product adoption and sales growth.

“The continuous publication of research data on Remsima SC has driven booth attendance to 1.5 times the usual level,” Celltrion Vice President and Head of Europe Ha Tae-hun said. “Leveraging our direct sales network across 20 European subsidiaries, Celltrion is committed to being more than just a pharmaceutical supplier—we strive to be a trusted partner for European IBD specialists.”